Consolidated Statements of Operations - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2017
Operating expenses:
Research and development (includes $3,893 and $0 of share-based compensation expense for the year ended March 31, 2017 and the period from February 2, 2016 (Date of Inception) to March 31, 2016, respectively)	$ 0	$ 43,500
General and administrative (includes $4,824 and $987 of share-based compensation expense for the year ended March 31, 2017 and the period from February 2, 2016 (Date of Inception) to March 31, 2016, respectively)	1,657	12,357
Total operating expenses	1,657	55,857
Other expense:
Changes in the fair value of the warrant liability	0	27,518
Other expense	0	139
Loss before provision for income tax	(1,657)	(83,514)
Income tax benefit	0	(74)
Net loss	$ (1,657)	$ (83,440)
Net loss per common share — basic and diluted (in USD per share)	$ (0.04)	$ (1.70)
Weighted average common shares outstanding — basic and diluted (in shares)	37,231,342	49,184,668